Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRN-31
- Development stage
- Preclinical
- Lead developer
- Sirana Pharma
- Modality
- Small Molecules
01
Overview
SRN-31 is a preclinical-stage small molecule therapeutic being developed by Sirana Pharma for the treatment of muscle diseases. Sirana Pharma specializes in musculoskeletal disorders, utilizing a proprietary targeting technology to deliver payloads specifically to bone and muscle tissues. While the company's lead assets, such as SRN-001, are typically siRNA-based conjugates, SRN-31 represents a small molecule approach within their portfolio. As of current public disclosures, the specific biological target and the exact muscle indication (e.g., muscle atrophy or sarcopenia) have not been detailed in the company's portfolio.
Beyond the preview
Go deeper on SRN-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRN-31.